DaltonTx, a UK-based technology company, today announces its exit from from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster. AI offers pharma a unique opportunity to discover medicines more effectively and […]
Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion Experienced team with a background in biotechnology and company building led by co-CEO’s Michael Krohn and Lukas Linnig Paul Scholz, the principal inventor of G-dase E technology, joins […]
Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases Continues strong momentum following 2024 emergence from stealth with $10M seed financing Dundee, Scotland – 13 January […]
Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader […]
Proprietary E3 ligase platform to enable protein stabilisation “at source”, thereby restoring the body’s sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges of drugging these targets Pipeline of first-in-class, small molecule, E3 ligase inhibitors to stabilise proteins and treat disease in several therapeutic areas, including […]
